Feb 11, 2022, 12:26 PM ETInterview, Fireside Chat

John Abramson: Big Pharma | Lex Fridman Podcast #263

The pharmaceutical industry prioritizes maximizing profits for investors and shareholders over optimizing American health.
The biggest solvable problem is rebalancing the equation so that medical knowledge serves patient health rather than commercial interests.
Drug companies routinely violate laws regarding marketing and data presentation; between 1991 and 2017, they paid $38 billion in fines.
Executives rarely face jail time for data misrepresentation, even in cases involving tens of thousands of deaths (e.g., Vioxx, OxyContin).
The "revolving door" between the FDA/CDC and Big Pharma creates systemic bias; John Abramson advocates for a lifetime ban on individuals moving from pharma to regulatory agencies.
In 2003, Billy Tauzin (then head of the Ways and Means Committee) authored the Medicare Part D law prohibiting drug price negotiation, then immediately left for a $2 million/year job at the pharmaceutical industry.

Peer reviewers currently do not have access to raw clinical trial data, preventing them from verifying accuracy or completeness.
Vioxx Case Study: In a 2000 New England Journal of Medicine study, Merck omitted three heart attacks from the data; inclusion would have shown the drug doubled heart attack risk.
FDA analysts knew of the omitted data but refused to run their analysis without it.
Clinical practice guidelines often rely on peer-reviewed publications that themselves rely on unverified data, creating a "stickiness" where doctors cannot easily retract beliefs once established.
Abramson proposes mandatory pre-publication transparency where peer reviewers sign confidentiality agreements to inspect raw data, and post-publication release of data for "citizen scientists" to audit.
Pfizer and the FDA have jointly opposed a Freedom of Information Act request to release vaccine data, arguing it would take months and cost $3 million (equating to one hour of vaccine sales).

Direct-to-consumer advertising in the U.S. is the only major exception globally; Abramson argues it cannot be banned but must be strictly regulated.
Proposed ad regulations would require:
- Disclosure of the "number needed to treat" (e.g., Trulicity requires treating 323 people to prevent one non-fatal event at a cost of $2.7 million).
- Mandatory comparison of drug efficacy against healthy lifestyle interventions.
- Clear disclosure of the true cost to society, not just the copay.
Advertising spend to doctors often exceeds spend on consumers, creating a "surround sound" network of influence that includes funding for medical education and journals.
Drug companies fund studies designed to prove "statistical significance" on marginal benefits rather than comparing efficacy to lifestyle changes (e.g., the Diabetes Prevention Program showed lifestyle changes were 58% effective vs. 31% for Metformin).
"Medicalizing" normal life struggles (e.g., sadness) has led to the overprescription of antidepressants, which show low efficacy for non-major depression.

Abramson identifies as pro-vaccine but suspects the withheld clinical trial data contains information embarrassing to the FDA or Pfizer, though real-world data confirms vaccine efficacy.
The U.S. paid a $50 billion request for global vaccination funding in 2021 to prevent variants; the money was unavailable because the same capital ($50 million) went to 32 billionaires in private wealth.
Pfizer expects to sell $65 billion in vaccines, making it the most profitable drug launch in history, while prioritizing first-world distribution where profits are highest.
Lack of global vaccine equity is predicted to result in new variants returning to harm the U.S. population, a risk pharmaceutical profit motives ignore.
mRNA technology infrastructure was built by the NIH; Pfizer merely paid royalties to avoid litigation and commercialized the application.

The U.S. spends 17.7% of GDP on healthcare (7% higher than the wealthy nation average) but ranks 68th in healthy life expectancy (down from 38th in 2000).
96% of U.S. clinical research funding goes to drugs and devices, while 80% of health determinants are lifestyle and social factors.
The "biomedical model" effectively transfers wealth from working Americans to investors without addressing the root causes of illness.
The NIH focuses on targets for commercial drug development rather than an epidemiological approach to population health.
Medicare is legally prohibited from negotiating drug prices, a clause inserted in 2003.

Abramson opposes censorship of anti-vaccine or scientific dissent, arguing the solution is better science communication and "defeating ideas with better ideas."
He warns that censorship is often performed by "C students" driven by outrage rather than reason, creating a backlash against trust in institutions.
The "medium is the message" on social media drives polarization and rage, which destroys the commons of discourse needed to find truth.
He suggests implementing a "peer review" style system for podcasts where independent experts add context or corrections in real-time or via appendices before publication.

On Morality: Most individuals in Big Pharma are good people whose ethical standards are warped by a culture that rewards profit maximization; they operate within a "bubble" where unethical acts become normalized.
On Leadership: Leaders like Francis Collins and Anthony Fauci bear responsibility for failing to shift the narrative toward health promotion and away from just "sickness" and drug development.
On Mortality: Abramson faced near-death experiences which he describes as "liberating," leading to a philosophy of committing one's whole heart to a cause that helps others.
On Meaning: The meaning of life is to care about something and do your best with it, whether as a doctor, gardener, or grandparent.
On the Future: He urges young people with a "calling" to enter medicine but to maintain the vigilance to question the "normal" that is dictated by corporate influence to prevent moral injury and burnout.